NVIC Articles

vaccine-history

Disease-Vaccine-Landing-Page/side-panel/vaccine-history

Latest articles

Browse Articles

Placeholder image
Page

In June 2023, the FDA’s VRBPAC met and voted to recommend that all COVID-19 vaccines manufactured for use in the United States be updated to target the Omicron XBB strain,...

Placeholder image
Page

An article published on September 30, 2021 in the European Journal of Epidemiology reported that vaccination has had no impact on COVID-19 rates. According to the published data that looked...

Placeholder image
Page

The B.1.1.529 variant (Omicron), which was initially identified in early November 2021 in South Africa, was labeled a Variant of Concern by WHO on November 26, 2021. According to WHO,...

Placeholder image
Page

In February 2021, the CDC stated that currently available mRNA COVID-19 vaccines would likely offer fully vaccinated individuals at least three months of vaccine-acquired immunity. In their quarantine guidance released...

Placeholder image
Page

In May 2021, Israeli health officials reported a possible link between the Pfizer COVID-19 vaccine and myocarditis after reporting that 62 cases had been reported following vaccination. Of these cases,...

Placeholder image
Page

The National Institute of Allergy and Infectious Diseases (NIAID) headed by Dr. Anthony Fauci issued a press release on March 16, 2020 announcing that a Phase 1 human clinical trial...

Placeholder image
Page

A COVID-19 vaccine using viral vector technology, Sputnik V, developed in partnership between the Russian research institution, the Gamaleya National Center of Epidemiology and Microbiology, and the Russian Direct Investment...

Placeholder image
Page

Convidicea. CanSino Biologics, Inc. of Tianjin, China, in partnership with China’s Academy of Military Medical Sciences’ Institute of Biotechnology, also began development of a COVID-19 vaccine, Convidicea (Ad5-nCoV), that employs...

Placeholder image
Page

AstraZeneca-University of Oxford COVID-19 vaccineA vaccine development team from the University of Oxford in the United Kingdom endeavored to make an experimental COVID-19 vaccine candidate by the end of the...

Placeholder image
Page

Maryland-based Novavax Inc, a biotechnology company which, prior to its COVID-19 vaccine, had never successfully delivered a product to market,  developed an experimental vaccine using recombinant nanoparticle technology. Referred to...

Topics
Select disease / vaccine